Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
ABSTRACT Despite substantial progress in KRAS‐targeted therapies, specific inhibitors of the KRAS G13D mutant remain unavailable. In a retrospective analysis, we found a notable downregulation of glutathione peroxidase 2 (GPX2) in KRAS G13D‐ mutant colorectal cancer (CRC), which correlated with poor outcomes. We hypoth...